Question normal

What are the current recommendations for screening high risk patients for breast and ovarian cancer and which imaging modalities are recommended? Are there any biochemical (genomic/proteinomic) markers being developed that would enable earlier detection with higher sensitivity/specificity compared to currently available markers such as CA-125?